288 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast PeerView Press

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Jay H. Shubrook, DO, FAAFP, FACOFP - Partnering With Peers and Patients: Achieving T2DM Treatment Goals With GLP-1 RA Therapy

    Jay H. Shubrook, DO, FAAFP, FACOFP - Partnering With Peers and Patients: Achieving T2DM Treatment Goals With GLP-1 RA Therapy

    Go online to PeerView.com/PVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in type 2 diabetes (T2DM) management discusses how to individualize treatment with GLP-1 RAs to improve outcomes for patients. Upon completion of this activity, participants should be better able to: Apply evidence-based treatment recommendations for GLP-1 RAs based on clinical trial results evaluating glycemic and extra-glycemic (eg, cardiovascular risk reduction, weight education) outcomes in patients with T2DM, Identify potential barriers to use (ie, mode of administration, adverse events) for current and emerging GLP-1 RAs, Engage in patient-centered discussions about the benefits and risks of using GLP-1 RAs to personalize management of T2DM.

    • 25 min
    Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs

    Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs

    Go online to PeerView.com/URQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs). Upon completion of this activity, participants will be able to: Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE, Assess the quality and validity of the evidence collected as part of real-world studies comparing the DOACs with warfarin in patients with VTE (eg, efficacy, safety, cost-effectiveness, quality of life), Incorporate RWE into clinical decision-making for patients with VTE to design individualized treatment plans, especially for patients who may not be well represented in randomized clinical trials.

    • 26 min
    Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

    Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

    Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.

    • 27 min
    Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

    Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

    Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

    • 1 hr 3 min
    Khaldoun G. Tarakji, MD, MPH - Adopting Telemedicine and Digital Tools for Nonvalvular Atrial Fibrillation Management and Stroke Prevention

    Khaldoun G. Tarakji, MD, MPH - Adopting Telemedicine and Digital Tools for Nonvalvular Atrial Fibrillation Management and Stroke Prevention

    Go online to PeerView.com/TWX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in cardiovascular medicine discuss the benefits of telemedicine when screening and caring for patients with nonvalvular atrial fibrillation (NVAF). Upon completion of this activity, participants will be able to: Identify the benefits of using telemedicine and remote care services to diagnose and manage patients with NVAF, Describe ways in which telemedicine and remote care services can be used to increase patient awareness about the risks of NVAF and overcome healthcare disparities to improve healthcare delivery for patients with untreated NVAF, Operationalize best practices to design processes and procedures for a telemedicine or remote care program to manage patients with NVAF and prevent stroke, Employ telemedicine and remote care services to diagnose and manage patients with NVAF during the COVID-19 pandemic and beyond.

    • 1 hr 28 min
    Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

    Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

    Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

    • 1 hr 16 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press